Pemvidutide is a novel, peptide-based glucagon-like peptide-1/glucagon dual receptor agonist. The Food and Drug Administration (FDA) has granted Fast Track designation to pemvidutide for the ...

Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH. Activation of the GLP-1 and glucagon receptors is ...

The company's lead candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist, has shown promising results in clinical trials for obesity and metabolic dysfunction-associated steatohepatitis ...

Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH. Activation of the GLP-1 and glucagon receptors is ...

Merck gains approval from FDA for efinopegdutide for the treatment of NASH. The FDA based its decision on data from a phase 2a, ... (GLP-1) and glucagon receptors, ...

GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

Merck & Co. says its dual GLP-1/glucagon receptor co-agonist efinopegdutide beat out Novo Nordisk's Ozempic in the tricky indication of nonalcoholic fatty liver disease (NAFLD). While NAFLD may be ...

For instance, glucagon-like peptide-1 (GLP-1) receptor agonists, which have made waves as therapies for diabetes and obesity, appear to hold promise for patients with MASLD and MASH, the authors said.

Semaglutide (Ozempic, Wegovy), a GLP-1 receptor agonist approved for type 2 diabetes and obesity (conditions linked with increased risk for NAFLD and NASH), has shown some potential in mid-stage ...

The dual GLP-1 and glucagon receptor agonist resulted in 'striking' weight loss in a phase 2 dosing trial of people with overweight or obesity ... Survodutide Has FDA Fast Track Designation for NASH.

And just like that, we have a crowded race to be the first approved NASH treatment—a market that could grow to $108.4 Billion globally by 2030.